Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled date : 2021 - 03 - 23 save search
Two Cell Therapy Companies Bag New CEOs
Published: 2021-03-23 (Crawled : 14:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.2%
H: 0.22%
C: -1.32%
therapy new ceo ceo leo
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
Published: 2021-03-23 (Crawled : 13:00) - biospace.com/
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: -0.85%
H: 0.74%
C: -5.04%
immunotherapy therapy respiratory
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Published: 2021-03-23 (Crawled : 12:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: -0.54%
H: 0.3%
C: -1.06%
treatment fda therapy fda approval keytruda
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
VRDN | $14.59 -3.76% -3.91% 1.5M
|
Health Care and Social Assistan...
|
| O: -2.66%
H: 0.56%
C: 0.56%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: -0.72%
H: 0.55%
C: -5.36%
biopharma liver therapy order
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.15%
H: 0.25%
C: -2.08%
treatment therapy cancer growth approval
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
Published: 2021-03-23 (Crawled : 08:00) - biospace.com/
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: 4.79%
H: 0.0%
C: -10.44%
covid disease therapy collaboration commercialization
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Published: 2021-03-23 (Crawled : 07:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.35%
H: 0.95%
C: 0.06%
prostate cancer positive therapy cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.